Charles River Laboratories International, Inc. beat EPS estimates 100% of the time across 16 reported quarters (16 beats, 0 misses), averaging +9.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $2.72 | $3.02 | +11.0% | Beat | |
| Q1 FY26 | $1.96 | $2.06 | +5.1% | Beat | |
| Q4 FY25 | $2.33 | $2.39 | +2.6% | Beat | Q4 FY25 call |
| Q3 FY25 | $2.32 | $2.43 | +4.7% | Beat | |
| Q2 FY25 | $2.50 | $3.12 | +24.8% | Beat | Q2 FY25 call |
| Q1 FY25 | $2.06 | $2.34 | +13.6% | Beat | |
| Q4 FY24 | $2.50 | $2.66 | +6.4% | Beat | |
| Q3 FY24 | $2.43 | $2.59 | +6.6% | Beat | |
| Q2 FY24 | $2.39 | $2.80 | +17.1% | Beat | |
| Q1 FY24 | $2.05 | $2.27 | +10.7% | Beat | |
| Q4 FY23 | $2.39 | $2.46 | +2.9% | Beat | |
| Q3 FY23 | $2.35 | $2.72 | +15.7% | Beat |
Back to CRL overview · CRL holders · CRL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.